Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Sentynl Therapeutics receives marketing authorization for NULIBRY® from the UK MHRA for treatment of MoCD Type A

Posted On: 2024-04-21 18:38:17 (Time Zone: IST)


Zydus Lifesciences Ltd. (Zydus), today announced that its wholly-owned subsidiary Sentynl Therapeutics, Inc. (Sentynl), has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients in Great Britain (GB) with Molybdenum Cofactor Deficiency (MoCD) Type A. This is an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants. It is known to impact fewer than 150 patients globally with a median survival age of four years.

NULIBRY® is a first-in-class synthetic cPMP substrate replacement therapy that was approved by the U.S. Food and Drug Administration (FDA) in 2021 to reduce the risk of mortality in patients with MoCD Type A. Following this decision by the UK MHRA, NULIBRY® is the first and only approved therapy in GB for MoCD Type A.

Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, "We are happy that with the UK MHRA approval of NULIBRY® which will enable access to this critical drug and treat an ultra-rare disorder. Healthcare providers in Great Britain can now bridge the unmet needs of patients with this innovative treatment."

Matt Heck, President & Chief Executive Officer of Sentynl said, "This approval advances our mission to make a positive impact in the lives of patients suffering from rare diseases, especially one as devastating as MoCD Type A."

NULIBRY®'s MHRA approval was supported by data from three clinical trials that demonstrated the safety and efficacy of NULIBRY for the treatment of patients with MoCD Type A compared to data from a natural history study. These studies showed that NULIBRYtreated patients had a 5.5 times lower risk of death than that of the untreated patients. Moreover, the survival probability at 3 years of age was 85.5% for NULIBRY®-treated patients and 55.1% for untreated control patients.

In March 2022, Sentynl acquired the global rights to NULIBRY® from BridgeBio Pharma, Inc. and is responsible for the ongoing development, manufacturing and commercialization of fosdenopterin globally.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 922.20 as compared to the previous close of Rs. 936.30. The total number of shares traded during the day was 50355 in over 4714 trades.

The stock hit an intraday high of Rs. 933.00 and intraday low of 913.25. The net turnover during the day was Rs. 46438289.00.


Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Shares of Go Digit General Insurance debuts on the bourses, closes 12% premium

New India Assurance reports 128.4% growth in profit after tax in Q 4FY 24

Astral Limited Launches Comprehensive New Paint Line as Astral Paints

HCLTech's AquaSphere solution wins SAP Pinnacle Award

Saregama Q4 FY24 Total Revenue at Rs.2,810 Mn

Godrej Properties achieves booking value of over INR 2,000 crore through the launch of its project Godrej Jardinia in Noida

L&T Technology Services announces Establishment of Simulation Centre of Excellence for Airbus

Ratnaveer Precision Engineering Ltd reports impressive growth with 23.94% increase in Net Profit, achieving Rs31.04 Crore in FY24

Metro Brands Ltd reports standalone YoY revenue growth of 11%

GRSE records highest ever Profit After Tax and Revenue from Operations during FY 24

Airtel Payments Bank Soars in FY24, Records INR 1,836 Crore of Revenue

Get ready for season 2 of #nofilter by IndiGo

Temp Shield Tiles: Saviour against Scorching Heat

Karur Vysya Bank opens its 840th Branch at Ayodhya today

JK Tyre records highest ever revenues and profits in FY24

HCLTech recognized as a Leader in Gartner® Magic Quadrant™ for Outsourced Digital Workplace Services

BPCL Boosts Aviation Fueling Capabilities with New Hydrant Facilities at Manohar International Airport

Sinclairs Hotels Total Income at ? 6512.59 lakh, up by 13.60%

Moneyboxx Finance reports strong turnaround in profitability in FY24

QubeHealth-Pay launches unique healthcare payment benefits for ION Exchange's 3000 employees

Explore the world with Bata's latest 'Try and Fly' campaign featuring 9 to 9 Collection

Gensol Engineering Ltd. strengthens leadership team with the appointment of Ms. Shilpa Urhekar as CEO, Solar EPC - India

IMFL Maker Tilaknagar Industries Profit After Tax jumps 20.9% in Q4, Revenue Increases to Rs 358.8 Crore

Balu Forge Industries Ltd Expands Forging Capacity

Trident Limited announces interim dividend of INR 0.36 per share for FY 2024-25

SBI General Insurance and Jana Small Finance Bank forge Bancassurance Partnership to increase insurance penetration

Rainbow Children's Medicare Limited recommends final dividend of Rs. 3

Poddar Pigments Limited recommends final dividend of Rs. 4

Ashok Leyland Expands its footprint in Northern India, inaugurates two Dealerships in Faridabad, and one in Greater Noida

Jupiter Wagons Ltd approves preferential issue of warrants to Tatravagonka A.S.

IRIS reports impressive results, enters the Rs 100 cr club

The India Cements Ltd Q4 FY2024 consolidated loss at Rs. 59.05 crores

Rainbow Children’s Medicare Limited consolidated Q4FY24 PAT drops to Rs. 50.97 crores

Poddar Pigments Ltd Q4FY24 profit up at Rs. 8.74 crore

Data Patterns record increased revenue in its Q4 results

Anupam Rasayan India Limited Reports Q4 & FY24 Results

YES BANK Targets India's Elite and Rising Affluent Class for Growth, Launches Premier Banking Services - YES Grandeur

NOD for IDFC First Bank Amalgamation

Modern Engineering and Projects Ltd receives order from Tata Steel Ltd

Waaree Renewable Technologies Ltd receives order worth Rs. 4.89 crore

Tata Sampann launches first of its kind Easy Cook Ragi Atta, a nourishing & convenient cooking choice

Dalmia Bharat boosts capacity with new cement mill of 1.0 MnT at its Ariyalur plant, Tamil Nadu

ESAF Small Finance Bank gets RBI nod for appointment of George Kalaparambil John as Executive Director

IIFL Home Finance becomes India's leading affordable housing finance company with AUM crossing ? 35,000 Crores

Piotex Industries stock makes bumper debut on BSE SME

HomeFirst achieves ?10,000 Crore AUM

RBI approves Mr. Pradeep Natarajan as Whole Time Director of IDFC FIRST Bank Limited

Fusion Micro Finance secures USD 25 million loan from U.S. International Development Finance Corporation

ITI Limited Bags LoIs worth Rs. 37.5 Cr for Solar Street light Systems in Bihar

JK Maxx Paints Launches #SingleBrandSharmaJi Campaign Reinforcing Commitment to Home Beautification


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020